trial

Treatment of Schizoaffective Disorder Using Mifepristone

NCTId NCT00725270
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Terminated
Enrollment 12 (actual)
Sponsored by Stanford University
Primary completion 2009-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
1998-04
Primary completion
2009-05
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Mifepristone

Sponsors

Stanford UniversityLead Sponsor
Pritzker Family FoundationCollaborator

Investigators

1
Jennifer KellerStudy Director

Sites

1 total
Stanford, United States

Linked catalysts

1
Treatment of Schizoaffective Disorder Using Mifepristone — primary completion2009-05

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE2,PHASE3
Primary Completion Date
2009-05
Status
TERMINATED
relationships
The graph out of here
drug
Mifepristone
drug
lead_sponsor
Stanford University
company
collaborator
Pritzker Family Foundation
company
indication
Psychotic Disorders
indication
Depressive Disorder
indication
Depressive Disorder, Major
indication
investigator
Jennifer Keller
person